Ranolazine Implantable Cardioverter-Defibrillator Trial
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1012 participants.
Also called NCT01215253
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,012 participants
- Sponsor
- Registry
-
NCT01215253
-
- Other papers using this trial's data
- Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial
- Reduction in Ventricular Tachyarrhythmia Burden in Patients Enrolled in the RAID Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada
- Registry status
- Completed
Technical summary
Registry record NCT01215253. Randomized; quadruple masking; primary purpose treatment. Start 2011-09 (registry gives no type); primary completion 2017-02-28 (actual). Results posted on 2018-06-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ranolazine Implantable Cardioverter-Defibrillator Trial
- Acronym
- RAID
- Condition
- Ischemic Cardiomyopathy
- Condition
- Nonischemic Cardiomyopathy
- Condition
- Heart Failure
- Intervention (Drug)
- Ranolazine
- Lead sponsor
- University of Rochester
Record details
- Record id
cardio:ct-nct01215253- Content hash
f1c5f24d8da53fa097387afedbb13364be7015adbc244e2cf783e5835b9d8a03